Is Centessa Pharmaceuticals plc (CNTA) a Buy, Sell, or Hold?
Centessa Pharmaceuticals plc
NASDAQ:CNTA
$40.5 USD
$0 (0.0%)
- Volume
- 0
- Average Volume
- 2.94M
- Market Capitalization
- $6.27B
- P/E Ratio
- -22.75
- Dividend Yield
- 93.83%
- Price Target
- $40.00
- Year High
- $40.56
- Year Low
- $12.78
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $9.53
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Mario Alberto Accardi |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | CNTA |
| CUSIP | 152309100 |
| CIK | 0001847903 |
| Web | https://www.centessa.com |
| Phone | 44 203 9206789 |
| Currency | USD |
| Employees | 129 |
| Country | GB |
Liquidity
| Debt-to-Equity Ratio | 0.02 |
| Payout Ratio | 0.00 |
| Current Ratio | 9.53 |
| Quick Ratio | 9.53 |
| Cash Ratio | 1.71 |
Sales & Book Value
| Annual Sales | $15M |
| Price / Sales | 0.00 |
| Cash Flow | -1.36 |
| Price / Cash Flow | -29.96 |
| Price / Book | 12.76 |
Price Target and Rating
| Average Stock Price Forecast | $40.00 |
| High Stock Price Forecast | $42.00 |
| Low Stock Price Forecast | $38.00 |
| Forecast Upside/Downside | 1.25% |
| Consensus Rating | N/A |
| Rating Score(0-5) | 0 |
| Research Coverage | 14 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1.46 |
| Trailing P/E Ratio | -22.75 |
| PEG Ratio | 3.15 |
| P/E Growth | 3.15 |
| Net Income | $-197.53M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -60.37% |
| Return on Assets | -39.05% |
Financials Score
| AltmanZ Score | 20.83 |
| Piotroski Score | 2.00 |
| Working Capital | 312.1M |
| Total Assets | 641.76M |
| Ebit | -261.5M |
| Market Cap | 6.27B |
| Total Liabilities | 154.42M |
Poll Results
About Centessa Pharmaceuticals plc (NASDAQ:CNTA) Stock
Centessa Pharmaceuticals plc operates as a clinical-stage pharmaceutical enterprise focused on discovering, developing, and ultimately providing therapeutic solutions to patients. The company's most advanced product candidates include Lixivaptan, a small molecule inhibitor of the vasopressin V2 receptor, which is currently undergoing Phase III clinical evaluation for treating autosomal dominant polycystic kidney disease. Additionally, SerpinPC, an activated protein C inhibitor, is progressing through Phase IIa clinical development for the management of hemophilia A and B. Centessa's pipeline also features several emerging assets in the clinical proof-of-concept stage. These comprise LB101 (a PD-L1xCD47 LockBody) and LB201 (a PD-L1xCD3 LockBody), both engineered to selectively activate pote ... nt CD47 and CD3 effector functions while minimizing systemic side effects. Another molecule, ZF874, is a small molecule pharmacological chaperone in Phase I studies, designed to correct the misfolding of the Z variant of alpha-1-antitrypsin, thus addressing alpha-1-antitrypsin deficiency. Furthermore, MGX292, a recombinant modified BMP9 replacement protein, aims to rectify the deficient BMP9 signaling implicated in Pulmonary Arterial Hypertension. The company is also developing OX2R Agonists, which are selective orexin receptor 2 agonists (available as oral and intranasal formulations) intended to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1 by leveraging structural insights. Beyond these, Centessa is exploring further clinical proof-of-concept compounds. CBS001, an anti-LIGHT antibody, is being investigated for inflammatory and fibrotic diseases due to its preferential binding to the inflammatory membrane form of LIGHT. Lastly, CBS004 is a humanized monoclonal antibody specifically targeting BDCA2, a protein found exclusively on plasmacytoid dendritic cells, with potential utility in conditions such as systemic sclerosis, systemic lupus erythematosus, and other autoimmune disorders. Centessa Pharmaceuticals plc was established in 2020 and is headquartered in Altrincham, United Kingdom.
Acquisition of Centessa by Lilly Approved by the High Court of Justice of England and Wales
2026-06-22 16:05:00
BOSTON and LONDON, June 22, 2026 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage company developing a new class of medicines for the treatment of excessive daytime sleepiness and other neurological conditions, which entered into a definitive agreement on March 31, 2026 relating to its proposed acquisition by Eli Lilly and Company (“Lilly”), through a wholly owned subsidiary, today announced that the High Court of Justice of England and Wales has approved the proposal for Lilly to acquire Centessa for $38.00 in cash per share plus one non-transferable contingent value right (“CVR”) that entitles the holder to receive up to an aggregate of $9.00 subject to the achievement of three milestones, for a total transaction value of approximately $7.8 billion (the “Transaction”).
2026-06-01 08:00:00
Proven Chief Medical Officer at several publicly listed and clinical-stage oncology companies with successful track record developing multiple modalities including radiotherapies from preclinical through global approvals across hematologic malignancies and solid tumors Played a leading role in clinical development and worldwide approvals of Erbitux® at Merck KGaA leading to its blockbuster status Led clinical development as CMO of NBE Therapeutics which was acquired by Boehringer Ingelheim for $1.4 billion, and most recently CMO of radiotherapy company Full-Life Technologies Timely key hire with Dr. Heeger's operational rigor and clinical expertise expected to elevate development of Actimab-A, ATNM-400, and Iomab-ACT as Actinium advances toward key data readouts and expanded clinical trials in 2H:2026 NEW YORK, June 1, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced the appointment of Steffen Heeger, MD, MSc, as Chief Medical Officer. Dr. Heeger brings a rare combination of radiotherapy expertise, global oncology drug development leadership, and public-company experience.
Are CNTA, WSR, GDOT Obtaining Fair Deals for their Shareholders?
2026-05-12 02:49:00
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
2026-05-11 12:43:00
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Centessa Pharmaceuticals plc (NasdaqGS: CNTA) to Eli Lilly and Company (NYSE: LLY). Under the terms of the proposed transaction, shareholders of Centessa will receive $38.00 in cash per share plus one non-transferrable contingent value right entitling the holder to receive up to an aggregate of.
2026-04-27 03:44:48
B. Metzler seel. Sohn and Co. AG purchased a new position in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ: CNTA) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 38,432 shares of the company's stock, valued at approximately $961,000. A number of other large investors
Frequently Asked Questions
-
What is the current Centessa Pharmaceuticals plc (CNTA) stock price?
-
Centessa Pharmaceuticals plc(NASDAQ:CNTA) stock price is $40.5 in the last trading session. During the trading session, CNTA stock reached the peak price of $40.56 while $12.78 was the lowest point it dropped to. The percentage change in CNTA stock occurred in the recent session was 0.0% while the dollar amount for the price change in CNTA stock was $0.
-
CNTA's industry and sector of operation?
-
The NASDAQ listed CNTA is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CNTA?
-
Mario Alberto Accardi | Chief Executive Officer & Director
Iqbal J. Hussain | Chief Legal Officer, Chief Compliance Officer & Company Secretary
Charlene Stoudt | Senior Vice President of Clinical Development Operations
Gregory Weinhoff | Chief Business Officer
Raphael Deferiere | Senior VP & Chief Accounting Officer -
How many employees does CNTA have?
-
Number of CNTA employees currently stands at 129. CNTA operates from 1 Ashley Road, Altrincham, None WA14 2DT, GB.
-
Link for CNTA official website?
-
Official Website of CNTA is: https://www.centessa.com
-
How do I contact CNTA?
-
CNTA could be contacted at phone #44 203 9206789 and can also be accessed through its website. CNTA operates from 1 Ashley Road, Altrincham, None WA14 2DT, GB.
-
How many shares of CNTA are traded daily?
-
The average number of CNTA shares traded daily for last 3 months was 2.94M.
-
What is the market cap of CNTA currently?
-
The market value of CNTA currently stands at $6.27B with its latest stock price at $40.5